University of Kansas
Dr. David B. Volkin is the Ronald T. Borchardt Distinguished Professor of Pharmaceutical Chemistry, and co-founder of the Vaccine Analytics and Formulation Center (VAFC) at The University of Kansas. The VAFC collaborates with global partners (non-profits, biopharma/vaccine companies, and academia) on analytical characterization and formulation development projects to facilitate novel vaccine and biotherapeutic drug candidates entering clinical trials.
Dr. Volkin joined the KU faculty in 2010 after a 20-year industry career in vaccine and biopharmaceutical R&D, including senior director positions at Merck Research Laboratories (Merck & Co.) and Centocor R&D (Johnson & Johnson). He led formulation and analytical groups that brought dozens of candidates into clinical trials, including five vaccines and three monoclonal antibodies approved for commercial use by regulatory agencies worldwide.
Dr. Volkin graduated with B.A. in Chemistry from the University of California-San Diego and earned a Ph.D. in Biochemical Engineering from the Massachusetts Institute of Technology. He is co-author of ~175 scientific publications and co-inventor on 15 U.S. patents including patents and papers describing the formulation and stabilization of the commercial HPV (Gardasil™) and rotavirus (RotaTeq™) vaccines. Dr. Volkin was awarded the American Association of Pharmaceutical Scientists (AAPS) Research Achievement Award in Biotechnology in 2015.
Tuesday, October 27, 2020
2:00 PM – 3:00 PM ET